收藏切换
Choice of perspectives of pharmacoeconomic evaluation to support the adjustment of national reimbursement drug list
收藏切换
Shijiao DENG1, Xuanqi QIAO1, Min HU1, 2, *, Wen CHEN1, 2
World Clinical Drug | 2022, 43(6) : 671 - 677
Less
收藏切换
World Clinical Drug | 2022, 43(6): 671-677
• Topic •
Choice of perspectives of pharmacoeconomic evaluation to support the adjustment of national reimbursement drug list
Full
Shijiao DENG1, Xuanqi QIAO1, Min HU1, 2, *, Wen CHEN1, 2
Affiliations
  • 1.School of Public Health, Fudan University, Shanghai 200032, China
  • 2.Center for Research and Evaluation in Pharmacoeconomics, Fudan University, Shanghai 200032, China
Published: 2022-06-10 doi: 10.13683/j.wph.2022.06.004
Outline
收藏切换

Pharmacoeconomic evaluation is an important tool for drug access and pricing decisions. The results of pharmacoeconomic evaluation carried out under different perspectives are different due to different costs and health outcomes they cover. However, the research perspective that should be adopted for the pharmacoeconomic evaluation to support the adjustment decision of the national reimbursement drug list in China (except Hong Kong, Macao and Taiwan) has not been clearly defined. Based on the submission guidelines of typical countries and regions, this paper analyzed the characteristics and applicable scenarios of different perspectives, and suggested that in China (except Hong Kong, Macao and Taiwan), started from the positioning of basic medical insurance system, the baseline analysis should be conducted from the perspective of basic medical insurance payers, and supplementary analysis should be conducted from other appropriate perspectives. Besides, the costs and health outcomes that should be included in the assessment under the corresponding perspective need to be specified in the submission guidelines.

national reimbursement drug list adjustment  /  pharmacoeconomic evaluation  /  perspective  /  guideline
邓诗姣, 乔渲淇, 胡敏, 陈文. 用于支持医保目录调整的药物经济学评价研究视角选取. 世界临床药物, 2022 , 43 (6) : 671 -677 . DOI: 10.13683/j.wph.2022.06.004
Shijiao DENG, Xuanqi QIAO, Min HU, Wen CHEN. Choice of perspectives of pharmacoeconomic evaluation to support the adjustment of national reimbursement drug list[J]. World Clinical Drug, 2022 , 43 (6) : 671 -677 . DOI: 10.13683/j.wph.2022.06.004
Year 2022 volume 43 Issue 6
9
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.06.004
  • Receive Date:2022-03-20
  • Online Date:2026-11-19
  • Published:2022-06-10
Article Data
Affiliations
History
  • Received:2022-03-20
Funding
Affiliations
    1.School of Public Health, Fudan University, Shanghai 200032, China
    2.Center for Research and Evaluation in Pharmacoeconomics, Fudan University, Shanghai 200032, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.06.004
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT